Drugs & Aging

, Volume 17, Issue 5, pp 399–410 | Cite as

Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus

A Risk-Benefit Assessment
Review Article

Abstract

Hormone replacement therapy (HRT) has been shown to be beneficial in reducing osteoporosis and alleviating climacteric symptoms. HRT has been suggested to reduce the risk for coronary heart disease (CHD), but data are controversial. Unopposed estradiol therapy seems to have a favourable effect on lipid profile and glucose tolerance whereas addition of a progestogen may attenuate these favourable metabolic changes.

Data on HRT in women with diabetes mellitus are scarce but of potential interest since these women are often characterised by hyperandrogenicity, insulin resistance and dyslipidaemia and are at a high risk for developing CHD. Present evidence suggests that short term unopposed oral estradiol therapy has a beneficial effect on glucose homeostasis, lipid profile and fibrinolytic activity, which may be compatible with a reduced risk for CHD. Accordingly, it may be hypothesised that HRT in women with diabetes mellitus may be at least as beneficial as in women without diabetes mellitus. However, women with diabetes mellitus are at increased underlying risk for venous thromboembolism and endometrial cancer. Whether HRT further increases this risk is not yet clear, but this possibility must be considered.

It is, however, likely that the benefits with HRT in postmenopausal women with diabetes mellitus outweigh the risks, but randomised studies are required before any more definite risk-benefit assessment can be made long term.

Keywords

Estrogen Coronary Heart Disease Postmenopausal Woman Estradiol Insulin Sensitivity 

References

  1. 1.
    Sturdee DW. Hormone replacement therapy: the benefits and risks. Prescr J 1994; 34: 234–42Google Scholar
  2. 2.
    Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992 Oct; 99: 821–8PubMedCrossRefGoogle Scholar
  3. 3.
    Grodstein FG, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75PubMedCrossRefGoogle Scholar
  4. 4.
    Grodstein FG, Stampfer MJ, Manson JAE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61PubMedCrossRefGoogle Scholar
  5. 5.
    Sourander L, Rajala T, Räihä I, et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998; 352: 1965–9PubMedCrossRefGoogle Scholar
  6. 6.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13PubMedCrossRefGoogle Scholar
  7. 7.
    Barrett-Connor E, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991; 265: 627–31PubMedCrossRefGoogle Scholar
  8. 8.
    United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165–75Google Scholar
  9. 9.
    Lindstedt G, Lundberg P-A, Lapidus L, et al. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. Diabetes 1991; 123–8Google Scholar
  10. 10.
    Haffner SM, Valdez RA, Morales PA, et al. Decreased sex-hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993; 77: 56–60PubMedCrossRefGoogle Scholar
  11. 11.
    Lapidus L, Lindstedt G, Lundberg P-A, et al. Concentrations of sex-hormone-binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986; 32: 146–52PubMedGoogle Scholar
  12. 12.
    Goddard M. The cost effectiveness of hormone replacement therapy: a review. Discussion paper 73. York: Centre for Health Economics, University of York, 1990Google Scholar
  13. 13.
    Matthews K, Meilahn E, Kuller L, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641–6PubMedCrossRefGoogle Scholar
  14. 14.
    Walton C, Godsland I, Proudler A, et al. The effects of menopause on insulin sensitivity, secretion and elimination in nonobese, healthy women. Eur J Clin Invest 1993; 23: 466–73PubMedCrossRefGoogle Scholar
  15. 15.
    Godsland IF, Walton C, Stevenson JC. Impact of menopause on metabolism. In: Diamond MP, Naftolin F, editors. Metabolism in the female life cycle. Rome: Ares Serono Symposia, 1993: 171–89Google Scholar
  16. 16.
    Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75PubMedCrossRefGoogle Scholar
  17. 17.
    Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531–4PubMedCrossRefGoogle Scholar
  18. 18.
    Manson JA, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus. Ann Epidemiol 1992; 2: 665–73PubMedCrossRefGoogle Scholar
  19. 19.
    Silfverstolpe G, Gustafson A, Samsioe G, et al. Lipid metabolic studies in oophorectomised women: effects induced by two different estrogens on serum lipids and lipoproteins. Gynecol Obstet Invest 1980; 11: 161–9PubMedCrossRefGoogle Scholar
  20. 20.
    Larsson-Cohn U, Wallentin L. Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. Acta Endocrinol 1977; 86: 583–96PubMedGoogle Scholar
  21. 21.
    Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208CrossRefGoogle Scholar
  22. 22.
    Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95PubMedGoogle Scholar
  23. 23.
    Thom M, Chakravarti S, Oram D, et al. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women. Br J Obstet Gynecol 1977; 84: 776–84CrossRefGoogle Scholar
  24. 24.
    Ajabor LN, Tsai CC, Vela P, et al. Effects of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 1972; 113: 383–7PubMedGoogle Scholar
  25. 25.
    Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846–53PubMedCrossRefGoogle Scholar
  26. 26.
    Luotola H, Pyörälä T, Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas 1986; 8: 245–53PubMedCrossRefGoogle Scholar
  27. 27.
    Crook D, Godsland IF, Hull J, et al. Hormone replacement therapy with dydrogesterone and 17 β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24-month follow-up. Br J Obstet Gynaecol 1997; 104(3): 298–304PubMedCrossRefGoogle Scholar
  28. 28.
    Matute M, Kalkhoff RK. Sex steroid influence on hepatic gluconeogenesis and glycogen formation. Endocrinology 1973; 92: 762–8PubMedCrossRefGoogle Scholar
  29. 29.
    Burke C. Biologically active cortisol in plasma of oestrogen-treated and normal subjects. BMJ 1969; 2: 798–800PubMedCrossRefGoogle Scholar
  30. 30.
    Rincon J, Holmäng A, Wahlström EÖ, et al. Mechanisms behind insulin resistance in rat skeletal muscle following oophorectomy and additional testosterone treatment. Diabetes 1996; 45: 615–21PubMedCrossRefGoogle Scholar
  31. 31.
    Andersson B, Mattsson L-Å, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638–43PubMedCrossRefGoogle Scholar
  32. 32.
    Brussaard HE, Leuven JA, Frölich M, et al. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40: 843–9PubMedCrossRefGoogle Scholar
  33. 33.
    Andersson B, Mattsson L-Å. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM. Acta Obstet Gynecol Scand 1999; 78: 260–1PubMedCrossRefGoogle Scholar
  34. 34.
    Mosnier-Pudar H, Faguer B, Guyenne TT, et al. Effects of deprivation and replacement by percutaneous 17 β-oestradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes. Arch Mal Coeur Vaiss 1991; 84: 1111–5PubMedGoogle Scholar
  35. 35.
    Andersson B, Mårin P, Lissner L, et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–11PubMedCrossRefGoogle Scholar
  36. 36.
    Hazzaul WR. Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Am J Obstet Gynecol 1989; 161: 1847–53Google Scholar
  37. 37.
    Lyons TJ, Lopes-Virella MF, Baystle JW. Glycation, oxidation, and glyoxidation in the pathogenesis of atherosclerosis in diabetes. Mod Med 1993; 61Suppl. 2: 4–8Google Scholar
  38. 38.
    Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentration and metabolism of lipoproteins. N Engl J Med 1991; 325: 1196–204PubMedCrossRefGoogle Scholar
  39. 39.
    Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest 1983; 72: 743–7PubMedCrossRefGoogle Scholar
  40. 40.
    Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–30PubMedCrossRefGoogle Scholar
  41. 41.
    Mijatovic V, Kenemans P, Netelenbos JC, et al. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3543–7PubMedCrossRefGoogle Scholar
  42. 42.
    Mattsson LÅ, Samsioe G, Schoultz B, et al. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. Br J Obstet Gynecol 1993; 100: 450–3CrossRefGoogle Scholar
  43. 43.
    Robinson JG, Folsom AR, Nabulsi AA, et al. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care 1996; 19: 480–5PubMedCrossRefGoogle Scholar
  44. 44.
    Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34PubMedCrossRefGoogle Scholar
  45. 45.
    Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88(Pt 1): 1421–30PubMedCrossRefGoogle Scholar
  46. 46.
    Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–4PubMedCrossRefGoogle Scholar
  47. 47.
    Basdevant A, DeLigneres B, Guy-Grand B. Differential lipemic and hormonal responses to oral and parenteral 17 beta-estradiol in postmenopausal women. Am J Obstet Gynecol 1983; 147: 77–81PubMedGoogle Scholar
  48. 48.
    Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998; 158: 617–21PubMedCrossRefGoogle Scholar
  49. 49.
    Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population: sixteenyear follow-up study. Diabetes Care 1990; 13: 631–54CrossRefGoogle Scholar
  50. 50.
    Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia 1997; 40: 711–7PubMedCrossRefGoogle Scholar
  51. 51.
    Darvi G, Catalons I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74CrossRefGoogle Scholar
  52. 52.
    Carmassi F, Morale M, Pucetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643–54PubMedCrossRefGoogle Scholar
  53. 53.
    Betteridge DJ. Diabetic dyslipidemia. Am J Med 1994; 96Suppl. 6A: 25–31SCrossRefGoogle Scholar
  54. 54.
    Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in non-insulin dependent diabetes. Circulation 1994; 90: I–50–3CrossRefGoogle Scholar
  55. 55.
    Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29: 691–9PubMedCrossRefGoogle Scholar
  56. 56.
    Kaplan RC, Heckbert SR, Weiss NS, et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 1998 Jul; 21: 1117–21PubMedCrossRefGoogle Scholar
  57. 57.
    Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91PubMedCrossRefGoogle Scholar
  58. 58.
    Fowlkes L, Sullivan JM. Estrogens, blood pressure and cardiovascular disease. Cardiol Rev 1995; 3: 106–14CrossRefGoogle Scholar
  59. 59.
    Stevenson JC. Assessments of therapeutic options for prevention of bone loss. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Copenhagen: Osteopress, 1987: 489–93Google Scholar
  60. 60.
    Bouillon R. Diabetic bone disease: low turnover osteoporosis related to decreased IGF-1 production. Verh K Acad Geneeskd Belg 1992; 54: 365–91PubMedGoogle Scholar
  61. 61.
    Saneshige S. Spinal bone mineral density in the female diabetic population [in Japanese]. Nippon Roonen Igakkai Zasshi 1992; 29: 864–73CrossRefGoogle Scholar
  62. 62.
    Wakasugi M, Wakao R, Tawata M, et al. Bone mineral density as measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14: 29–33PubMedCrossRefGoogle Scholar
  63. 63.
    Stevenson JC, Lees B, Devenport M, et al. Determinants of bone density in normal women: risk factors for future osteoporosis. BMJ 1989; 298: 924–8PubMedCrossRefGoogle Scholar
  64. 64.
    Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 1992; 48: 345–55PubMedGoogle Scholar
  65. 65.
    Persson I, Adami HO, Bergkvist L. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1988; 298: 147–51CrossRefGoogle Scholar
  66. 66.
    La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950–3PubMedCrossRefGoogle Scholar
  67. 67.
    Maatela J, Aromaa A, Salmi T. The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir et Gynaecol 1994; 208 Suppl.: 20–4Google Scholar
  68. 68.
    Dahlgren E, Friberg L-G, Johansson S, et al. Endometrial carcinoma: ovarian dysfunction — a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991; 41: 143–50PubMedCrossRefGoogle Scholar
  69. 69.
    Lapidus L, Helgesson O, Merck C, et al. Adipose tissue distribution and female carcinomas: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Int J Obes 1988; 12: 361–8PubMedGoogle Scholar
  70. 70.
    Lundgren H, Bergström C, Blohme G, et al. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: results from a prospective study in Gothenburg, Sweden. Int J Obes 1989; 13: 413–23PubMedGoogle Scholar
  71. 71.
    Stanford JL, Weiss NS, Voigt LF, et al. Combined oestrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137–42PubMedCrossRefGoogle Scholar
  72. 72.
    Folsom AR, Minic PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Publ Health 1995; 85: 1128–31CrossRefGoogle Scholar
  73. 73.
    Whitcroft SIJ, Stevenson JC. Hormone replacement therapy: risks and benefits. Clin Endocrinol 1992; 36: 15–20CrossRefGoogle Scholar
  74. 74.
    Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93PubMedCrossRefGoogle Scholar
  75. 75.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59CrossRefGoogle Scholar
  76. 76.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of ral oxifene on risk of breast cancer in postmenopausal women: results from the MORE trial. JAMA 1999; 281: 2189–97PubMedCrossRefGoogle Scholar
  77. 77.
    Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic aspects. Diabetologia 1993; 36: 1119–25PubMedCrossRefGoogle Scholar
  78. 78.
    Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–8PubMedCrossRefGoogle Scholar
  79. 79.
    Ceriello A, Quatraro A, Marchi E, et al. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet Med 1990; 7: 343–8PubMedCrossRefGoogle Scholar
  80. 80.
    Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone therapy. Lancet 1996; 348: 977–80PubMedCrossRefGoogle Scholar
  81. 81.
    Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3PubMedCrossRefGoogle Scholar
  82. 82.
    Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–8PubMedCrossRefGoogle Scholar
  83. 83.
    Hahn L, Mattsson L-Å, Andersson B, et al. The effects of estrogen replacement therapy on haemostasis variables in postmenopausal women with noninsulin-dependent diabetes mellitus. Blood Coag Fibrinol 1999; 10: 81–6CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of MedicineSahlgrenska University Hospital/Sahlgrenska, Göteborg UniversitySweden

Personalised recommendations